Iterum Therapeutics plc (ITRMF)
OTCMKTS
· Delayed Price · Currency is USD
0.0100
-0.0050 (-33.33%)
At close: Apr 29, 2026
Iterum Therapeutics Revenue
Iterum Therapeutics had revenue of $390.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $390.00K.
Revenue (ttm)
390.00K
Revenue Growth
n/a
P/S Ratio
2.03
Revenue / Employee
43.33K
Employees
9
Market Cap
792.53K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Eastgate Biotech | 137.64K |
| International Stem Cell | 9.10M |
| Evofem Biosciences | 20.18M |
| LakeShore Biopharma | 84.75M |
| Lyra Therapeutics | 398.00K |
| Halberd | 6.94K |
Iterum Therapeutics News
- 4 weeks ago - Iterum files wind-up petition due to limited cash, inability to raise equity - Reuters
- 4 weeks ago - Iterum Therapeutics Announces Filing of Winding Up Petition - GlobeNewsWire
- 2 months ago - Iterum Therapeutics Provides Business Update - GlobeNewsWire
- 5 months ago - Iterum Therapeutics Earnings Call Transcript: Q3 2025 - Transcripts
- 5 months ago - Iterum Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 - GlobeNewsWire
- 7 months ago - Iterum Therapeutics to Present Data at IDWeek 2025 - GlobeNewsWire
- 9 months ago - Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - GlobeNewsWire